Since the primary cause of cervical cancer progression is VEGF-driven angiogenesis, anti-angiogenic therapy has recently emerged as a promising strategy in the treatment of persistent, metastatic, or recurrent cervical cancer [15]. The gene discussed is VEGFA; the disease is cervical carcinoma.